<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>431</serviceExecutionTime><Drug id="68000"><DrugName>OX-ESI</DrugName><DrugSynonyms><Name><Value>OX-ESI</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>15-lipoxygenase inhibitors (inflammation), Orexo/Ortho-McNeil-Janssen</Value></Name></DrugSynonyms><CompanyOriginator id="27664">Orexo AB</CompanyOriginator><CompaniesSecondary><Company id="17421">Janssen Pharmaceutica NV</Company><Company id="25863">Janssen Pharmaceuticals Inc</Company><Company id="27664">Orexo AB</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17421" type="Company"><TargetEntity id="4295987443" type="organizationId">Janssen Pharmaceutica NV</TargetEntity></SourceEntity><SourceEntity id="25863" type="Company"><TargetEntity id="4296827622" type="organizationId">Janssen Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="27664" type="Company"><TargetEntity id="4295890191" type="organizationId">Orexo AB</TargetEntity></SourceEntity><SourceEntity id="713" type="ciIndication"><TargetEntity id="10068956" type="MEDDRA"></TargetEntity><TargetEntity id="3886" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="9182" type="Action"><TargetEntity id="1382" type="Mechanism">15-Lipoxygenase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="713">Respiratory tract inflammation</Indication></IndicationsSecondary><ActionsPrimary><Action id="9182">15-Lipoxygenase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-30T09:07:29.000Z</LastModificationDate><ChangeDateLast>2016-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>2010-09-06T15:30:20.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25863" linkType="Company"&gt;Janssen Pharmaceuticals&lt;/ulink&gt; (formerly &lt;ulink linkID="25863" linkType="Company"&gt;Ortho-McNeil-Janssen Pharmaceuticals&lt;/ulink&gt;) and &lt;ulink linkID="17421" linkType="Company"&gt;Janssen Pharmaceutica&lt;/ulink&gt;, under license from &lt;ulink linkID="27664" linkType="Company"&gt;Orexo&lt;/ulink&gt;, were investigating OX-ESI, an oral 15-lipoxygenase (15-LO) inhibitor, for the potential treatment of inflammatory disorders, such as asthma and chronic obstructive pulmonary disease (COPD) [&lt;ulink linkID="1128332" linkType="Reference"&gt;1128332&lt;/ulink&gt;], [&lt;ulink linkID="1128607" linkType="Reference"&gt;1128607&lt;/ulink&gt;]. In January 2012, the collaboration was ended, and the program was closed [&lt;ulink linkID="1258811" linkType="Reference"&gt;1258811&lt;/ulink&gt;], [&lt;ulink linkID="1258810" linkType="Reference"&gt;1258810&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25863">Janssen Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="713">Respiratory tract inflammation</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1258810" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="713">Respiratory tract inflammation</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1258810" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27664">Orexo AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="713">Respiratory tract inflammation</Indication><StatusDate>2010-06-01T00:00:00.000Z</StatusDate><Source id="1128332" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="713">Respiratory tract inflammation</Indication><StatusDate>2010-06-01T00:00:00.000Z</StatusDate><Source id="1128332" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25863">Janssen Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="713">Respiratory tract inflammation</Indication><StatusDate>2010-06-01T00:00:00.000Z</StatusDate><Source id="1128332" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02107"><Name>15-Lipoxygenase</Name><SwissprotNumbers><Swissprot>O15296</Swissprot><Swissprot>O35936</Swissprot><Swissprot>P12530</Swissprot><Swissprot>P16050</Swissprot><Swissprot>Q5RBE8</Swissprot><Swissprot>Q8K4F2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27664">Orexo AB</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="131729" title="Janssen Pharmaceuticals to develop Orexo's OX-CLI and OX-ESI programs worldwide"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>